Physician profile
Peter Chang
NPI 1891961017
$50,261.26
in general payments reported to CMS, 2019-2025
11 companies · $204 in 2025
The $204 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $266 · 2021: $625 · 2022: $361 · 2023: $445 · 2024: $12K · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $11K · Food and Beverage: $1,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $11,411.16 |
| Food and Beverage | $1,098.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $36,736.08 | 2019-2022 | |
| Johnson & Johnson Health Care Systems INC. | $11,411.16 | 2024 | |
| Abbvie INC. | $731.37 | 2023-2025 | Natrelle Saline-Filled Breast Implants |
| Merz North America, INC. | $704.81 | 2019-2025 | |
| Acelrx Pharmaceuticals, INC. | $240.57 | 2021-2022 | |
| Sientra, INC. | $183.11 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.25 | 2022-2025 | Jardiance |
| Vertical Pharmaceuticals, LLC | $40.48 | 2023-2024 | Dsuvia |
| Smith+Nephew, INC. | $34.27 | 2019-2020 | |
| Mentor Worldwide LLC | $32.33 | 2023 | Mentor Memorygel Resterilizable Gel Sizer |
| Tela Bio, INC. | $18.83 | 2024 | Ovitex 2s |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.